Statin-induced coronary artery disease regression rates differ in men and women

Current Opinion in Lipidology

Volumn 26, Issue 4, 2015, Pages 276-281

  Puri, Rishi ^a   Nissen, Steven E ^a   Nicholls, Stephen J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Atorvastatin; IVUS; plaque regression; rosuvastatin; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROMA; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY DISSECTION; DISEASE COURSE; FIBROMUSCULAR DYSPLASIA; HUMAN; INTRAVASCULAR ULTRASOUND; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SUDDEN CARDIAC DEATH; TREATMENT RESPONSE; FEMALE; MALE; PLAQUE, ATHEROSCLEROTIC; SEX RATIO; TREATMENT OUTCOME;

CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLAQUE, ATHEROSCLEROTIC; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 84941369721     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000195     Document Type: Review

References (30)

1. Kendrick M. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No. BMJ 2007; 334:983.
2. Grundy SM. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. BMJ 2007; 334:982.
3. Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012; 59:572-582.
4. Mosca L. Sex, statins, and statistics. Lancet 2015; 385:1368-1369.
5. Victor BM, Teal V, Ahedor L, Karalis DG. Gender differences in achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol 2014; 113:1611-1615.
6. Virani SS, Woodard LD, Ramsey DJ, et al. Gender disparities in evidencebased statin therapy in patients with cardiovascular disease. Am J Cardiol 2015; 115:21-26.
7. Cholesterol Treatment Trialists C. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015.
8. Puri R, Tuzcu EM, Nissen SE, Nicholls SJ. Exploring coronary atherosclerosis with intravascular imaging. Int J Cardiol 2013; 168:670-679.
9. Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010; 55:2399-2407.
10. Puri R, Wolski K, Uno K, et al. Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events. J Am Coll Cardiol Cardiovasc Interv 2013; 6:29-35.
11. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365:2078-2087.
12. Puri R, Nissen SE, Shao M, et al. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. J Am Coll Cardiol Cardiovasc Imaging 2014; 7:1013-1022.
13. Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015; 131:434-441.
14. Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001; 141:735-741.
15. Han SH, Bae JH, Holmes DR Jr, et al. Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J 2008; 29:1359-1369.
16. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to genderbased pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006; 47:S21-29.
17. Burke AP, Farb A, Malcom GT, et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998; 97:2110-2116.
18. Saw J, Ricci D, Starovoytov A, et al. Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. J Am Coll Cardiol Cardiovasc Interv 2013; 6:44-52.
19. Saw J, Aymong E, Sedlak T, et al. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ Cardiovasc Interv 2014; 7:645-655.
20. Bairey Merz CN, Mark S, Boyan BD, et al. Proceedings from the scientific symposium: sex differences in cardiovascular disease and implications for therapies. J Womens Health (Larchmt) 2010; 19:1059-1072.
21. van den Bouwhuijsen QJ, Vernooij MW, Hofman A, et al. Determinants of magnetic resonance imaging detected carotid plaque components: the Rotterdam study. Eur Heart J 2012; 33:221-229.
22. Ruiz-Garcia J, Lerman A, Weisz G, et al. Age-and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study. EuroIntervention 2012; 8:929-938.
23. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol 2009; 54:1561-1575.
24. Nicholls SJ, Wolski K, Sipahi I, et al. Rate of progression of coronary atherosclerotic plaque in women. J Am Coll Cardiol 2007; 49:1546-1551.
25. Puri R, Nissen SE,BallantyneCM, et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J 2013; 34:1818-1825.
26. Truong QA, Murphy SA, McCabe CH, et al. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes 2011; 4:328-336.
27. Bergheanu SC, Reijmers T, Zwinderman AH, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin 2008; 24:2477-2487.
28. Schissel SL, Jiang X, Tweedie-Hardman J, et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 1998; 273:2738-2746.
29. Jeong T, Schissel SL, Tabas I, et al. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998; 101:905-912.
30. Jiang XC, Paultre F, Pearson TA, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20:2614-2618.